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Adjuvants enhance immunity to vaccines and experimental antigens by a variety of mechanisms. In the past
decade, many receptors and signaling pathways in the innate immune system have been defined and these
innate responses strongly influence the adaptive immune response. The focus of this review is to delineate
the innate mechanisms by which adjuvants mediate their effects. We highlight how adjuvants can be used to
influence the magnitude and alter the quality of the adaptive response in order to provide maximum protec-
tion against specific pathogens. Despite the impressive success of currently approved adjuvants for gener-
ating immunity to viral and bacterial infections, there remains a need for improved adjuvants that enhance
protective antibody responses, especially in populations that respond poorly to current vaccines. However,
the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant
vaccine antigens.Introduction
Many of themost effective and safe vaccines are live, attenuated
variants of the targeted pathogen. Their administration results in
mild, usually asymptomatic, infection, but generates long-lived
immunity similar to that observed in individuals who recover
from natural infection. For many pathogens, however, attenu-
ated vaccines have not been successfully developed. For others,
such as influenza, they are impractical, because natural infection
itself does not confer adequate immunity. To vaccinate against
such organisms, nonliving antigens are used, ranging from
whole, inactivated viruses and microorganisms to single
recombinant antigens.
Nonliving vaccine antigens, especially purified or recombinant
subunit vaccines, are often poorly immunogenic and require
additional components to help stimulate protective immunity
based on antibodies and effector T cell functions. These
additional components, termed adjuvants, provide the ‘‘help’’
(from adjuvare, to help) needed to enhance the immunogenicity
of vaccine antigens. Adjuvants currently in widespread use,
either in man or in animals, have for the most part been
developed empirically, without a clear understanding of their
cellular and molecular mechanisms of action. However, recent
data suggest that most, if not all, adjuvants enhance T and B
cell responses by engaging components of the innate immune
system, rather than by direct effects on the lymphocytes them-
selves (McCartney et al., 2009; McKee et al., 2007, 2010;
O’Hagan and De Gregorio, 2009).
Why Use an Adjuvant?
Adjuvants have been traditionally used to increase the magni-
tude of an adaptive response to a vaccine, based on antibody
titer or ability to prevent infection, but a second role for adjuvants
has become increasingly important: guiding the type of adaptive
response to produce the most effective forms of immunity for
each specific pathogen (Kenney and Cross, 2010; Pulendran
et al., 2010). Thus, there are two distinct reasons to incorporate492 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.an adjuvant into a vaccine. Adjuvants are currently used clinically
to: (1) increase the response to a vaccine in the general popula-
tion, increasing mean antibody titers and/or the fraction of
subjects that become protectively immunized; (2) increase
seroconversion rates in populations with reduced responsive-
ness because of age (both infants and the elderly), disease, or
therapeutic interventions, as in the use on the MF59 adjuvant
to enhance the response of older subjects to influenza vaccine
(Beran, 2008; Podda, 2001); (3) facilitate the use of smaller doses
of antigen (Banzhoff et al., 2009; Boyle et al., 2007; Schwarz
et al., 2009), because the ability of an adjuvant to permit compa-
rable responses with substantially lower amounts of antigen
could be important in circumstances in which large-scale
vaccination is urgent and production facilities limiting, as in the
emergence of a pandemic influenza strain; and (4) permit
immunization with fewer doses of vaccine. The requirement of
many vaccines for multiple injections presents compliance
issues and, in much of the world, significant logistic challenges.
Adjuvants can reduce the number of doses required to achieve
protection (Banzhoff et al., 2009; Halperin et al., 2006; Schwarz
et al., 2009).
The second reason for incorporating an adjuvant into a vaccine
is to achieve qualitative alteration of the immune response. For
vaccines currently under development, adjuvants are increas-
ingly used topromote types of immunity not effectively generated
by the nonadjuvanted antigens. For example, adjuvants have
been used in preclinical and clinical studies to: (1) provide func-
tionally appropriate types of immune response (e.g., T helper 1
[Th1] cell versus Th2 cell, CD8+ versusCD4+ T cells, specific anti-
body isotypes) (Table 1); (2) increase the generation ofmemory—
especially T cell memory (Galli et al., 2009b; Leroux-Roels et al.,
2010; Vandepapeliere et al., 2008); (3) increase speed of initial
response, which may be critical in a pandemic outbreak of infec-
tion (Galli et al., 2009a; Huleatt et al., 2007; Khurana et al., 2010);
and (4) alter the breadth, specificity, or affinity of the response
(Khurana et al., 2010; Malherbe et al., 2008).
Table 1. Triggering of the Innate and Adaptive Components of the Immune System by Major Adjuvants
Adjuvant
Major Immunostimulatory
Component(s)
Innate Receptors or
Pathway Activated
Principal Immune Responses
Stimulated
Licensed Adjuvants
Alum aluminum salts NLRP3 inflammasome (?) Ab, Th2 (+ Th1 in humans)
MF59 and AS03 squalene-in-water
emulsions
tissue inflammation
(no receptors defined)
Ab, Th1 + Th2
AS04 MPL plus alum TLR4 and inflammasome (?) Ab, Th1
Adjuvants in Widespread Experimental Use or in Late Stage Clinical Development
Poly-IC (also Poly-ICLC) synthetic derivatives of dsRNA TLR3, MDA5 Ab, Th1, CD8+ T cells
MPL and formulations
(AS01, AS02)
MPL and QS-21 TLR4 (MPL), ? (QS21) Ab, Th1
Flagellin, flagellin-Ag
fusion proteins
Flagellin from S. typhimurium TLR5 Ab, Th1 + Th2
Imiquimods imidazoquinoline derivatives TLR7, TLR8 or both Ab, Th1, CD8+ T cells (when conjugated)
CpG oligodeoxynuceotides
and formulations (IC31, QB10)
synthetic phophorothioate-linked DNA
oligonucleotides with optimized CpG
motifs
TLR9 Ab, Th1, CD8+ T cells (when conjugated)
CAF01 trehalose dimycolate (cord factor) Mincle Ab, Th1, Th17
ISCOMS and ISCOMATRIX saponins mechanism undefined Ab, Th1+ Th2, CD8+ T cells
IFA (and Montanide
formulations)
mineral or paraffin oil + surfactant mechanism undefined Ab, Th1 + Th2
CFA IFA + peptidoglycan,
trehalose dimycolate
NLR, inflammasome,
Mincle, TLR?
Ab, Th1, Th17
The principal immune response stimulated is based on results from human and mouse studies, although it may be limited to one species in some
cases. Where indicated, conjugation of TLR ligand to antigen is necessary to obtain significant CD8+ T cell responses.
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Versus Cellular Immunity
Most current vaccines confer protection primarily through
humoral immunity (Plotkin, 2010). Responses are elicited by
a variety of vaccine platforms that include live attenuated,
recombinant protein, toxoids, or polysaccharide-protein conju-
gates. Antibody responses to many current vaccines are
long-lived and require infrequent or no additional boosting to
sustain protection (Amanna et al., 2007). Despite the impressive
success of such vaccines, there are substantial groups of people
for which current vaccines, even those using alum adjuvant, do
not achieve adequate seroconversion rates or protective anti-
body titers. Moreover, responses to vaccines begin to decline
in healthy adults after 40–50 years of age (Chen et al., 2009)
and as a result of health conditions such as chronic kidney
disease (Beran, 2008). The addition of an adjuvant to an existing
vaccine, as has been done for influenza (Podda, 2001), or
a switch from alum to a more effective adjuvant, as for hepatitis
B virus (HBV) (Beran, 2008; Halperin et al., 2006), represents
a substantial benefit for these groups.
For polarization of helper T cell, there are striking differences in
the type of response preferentially stimulated by different adju-
vants. Adjuvants such as MF59 and ISCOMs (Table 1), as well
as Toll-like receptor 2 (TLR2) and TLR5 ligands, enhance T cell
and antibody responses without altering their Th1/Th2 cell
balance of the specific antigens. In contrast, more polarized
Th1 cell responses are elicited by adjuvants that incorporate
agonists of TLR3, TLR4, TLR7-TLR8, and TLR9. Complete
Freund’s adjuvant (CFA) and CAF01 induce mixed Th1 andTh17 cell responses. Thus, selection of an appropriate adjuvant
is influenced by the type of CD4+ T cell response required for
protection.
A more daunting challenge is developing adjuvants that will
generate protective CD8+ T cell responses to soluble proteins.
Here, the type of vaccine is dictated by the particular processing
pathway of MHC class I presentation. Vaccines that lead to
direct infection of cells, such as viral vectors or DNA, induce
CD8+ T cell immunity through the endogenous class I presenta-
tion pathway; however, exogenous protein vaccines require
cross-presentation. To promote differentiation of functional
CD8+ T cells, a successful adjuvant must be given with a protein
formulated in a manner that facilitates entry into the MHC class I
processing pathway, trigger dendritic cell (DC) activation, and
induce type-I interferon (IFN) production.
The difficulty in generating potent and durable T cell immunity
with current vaccines and adjuvants has profound clinical impli-
cations for a variety of diseases. There are still no fully effective
vaccines against many widespread infectious diseases,
including HIV-AIDS, malaria, and tuberculosis. Although humoral
immunity has a clear role in preventing infection by HIV (Mascola
et al., 2000) and can influence certain stages of malaria infection
(Moorthy and Ballou, 2009), there is compelling evidence that
Th1 cells, CD8+ T cells, or both also have a critical role in prevent-
ing or controlling these infections. More challenging still is the
task of developing adjuvants for therapeutic treatment of
cancers and chronic viral infections, where it will be necessary
to generate potent and perhaps multifunctional T cell responses
in patients who respond poorly to the relevant tumor or viralImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 493
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(Gale and Foy, 2005; Rosenberg et al., 2004). For such vaccines,
themajor hurdles for an adjuvant will be to stimulate CD8+ T cells
and to circumvent the regulatory mechanisms that limit the host
response to the tumor or pathogen. Together, these examples
underscore the critical need to develop vaccines capable of
inducing potent and durable T cell immunity in man.
Innate Immunity
Microbial detection by the innate system relies heavily on
pattern recognition receptors (PRRs), which recognize molec-
ular structures common to large groups of microbes (Beutler,
2009; Takeuchi and Akira, 2010). PRRs are encoded in the
germline and not subject to somatic variation, unlike the antigen
receptors of T and B lymphocytes, which are somatically gener-
ated and clonally distributed. PRRs do not have the exquisite
specificity of the T and B cell antigen receptors of adaptive
immunity, but permit detection of a wide range of potential
pathogens by a small number of receptor genes undergoing
constant evolutionary selection. However, discussions of the
innate and adaptive immune systems often present them as
two coexisting systems, whereas, in reality, the sophisticated
recognition systems of adaptive immunity are evolutionarily
superimposed upon the innate immune system and are fully
integrated with it. Thus, both T and B cells express multiple
innate recognition receptors and many of the ultimate effector
functions of adaptive responses utilize cells and molecules of
the innate system.
Innate responses are typically more rapid than adaptive
responses, with the generation of substantial host defense
occurring within minutes to hours of infection, rather than days
to weeks as is typical of adaptive responses. However, innate
responses wane rapidly, the result of multiple mechanisms of
feedback regulation, in order to limit the tissue damage that
can result from these potent, relatively nonspecific effector
mechanisms. Unlike T and B cell responses, innate responses
typically do not lead to memory, meaning that a subsequent
encounter with a microbial pattern does not produce a faster
or more intense response than the initial one.
The past 20 years have seen a revolution in our under-
standing of the cells, receptors, and molecules that contribute
to innate immunity and in the ways that the innate response
directs the subsequent adaptive immune response (Fearon
and Locksley, 1996; Iwasaki and Medzhitov, 2010). The list of
agents that have been used to enhance the immunogenicity
of vaccines and experimental antigens is extensive (Kenney
and Cross, 2010; Pulendran et al., 2010). In this review, we
will focus on two categories of adjuvants: established ones
that are widely used clinically or experimentally and newer adju-
vant candidates for which substantial mechanistic data are
available. As additional innate pathways of immunity are dis-
covered, novel adjuvants need be developed with a clear ap-
preciation of the cellular and molecular events responsible for
their activity and a reasonable hypothesis for the type of
responses needed to confer protective immunity to the target
pathogen. It is no longer sufficient to develop an adjuvant solely
on empirical studies, forgoing a basic understanding of its
mechanism of action until long after it has been approved for
human use.494 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.How Do Adjuvants Engage the Innate Immune System?
Adjuvants in widespread clinical or experimental use have long
been regarded as either immunostimulatory agents or as passive
depots or vehicles. Most immunostimulatory adjuvants are
ligands for PRR, although some (not discussed in this review)
act by providing a key component of the innate response
(cytokines) or by stimulating an activation pathway directly,
bypassing the innate receptor (toxins). However, it is now
becoming clear that adjuvants once thought to act primarily as
depots or formulations, such as alum and emulsions, trigger
innate responses and these responses are central to their
adjuvant activity (Maraskovsky et al., 2009; Marrack et al.,
2009; McKee et al., 2010; Mosca et al., 2008). For these widely
used adjuvants there are extensive efficacy data, and substantial
human safety databases for vaccines with alum, MF59, AS03,
and AS04. For this reason, it is important to define the innate
receptors and pathways utilized by these existing, empirically
derived adjuvants and to try to establish correlations between
observed safety and efficacy and mechanisms of action.
Members of nearly all of the PRR families are potential targets
for adjuvants. These include TLRs recognizing lipids, lipopro-
teins, nucleic acids, and proteins; NOD-like receptors (NLR,
also defined as ‘‘nucleotide-binding domain and leucine-rich
repeat containing’’ receptors) responding to multiple ligands
such as peptidoglycan species, flagellin, toxins, and ATP;
helicases (RIG-I-like receptors, RLR) triggered by cytoplasmic
RNA; and C-type lectin receptors (CLRs) recognizing carbohy-
drates and lipids (Beutler, 2009; Iwasaki and Medzhitov, 2010;
Kawai and Akira, 2010; Takeuchi and Akira, 2010). They signal
through pathways involving distinct adaptor molecules and
intermediates such as MyD88, TRIF, RIP2, CARD9, and IPS-1
that partially dictate the outcome of receptor-ligand interaction.
Two key transcriptional programs involving the transcription
factors NF-kB, IRF-3, and IRF-7 are activated by these signaling
circuits, resulting in the induction of genes encoding cytokines,
chemokines, and costimulatory molecules that play a key role
in priming, expansion, and polarization of immune responses
(O’Neill and Bowie, 2010).
Signaling pathways triggered by constituents of damaged or
dying host cells can also contribute to the function of adjuvants.
This process occurs in part through the inflammasome, a molec-
ular complex that activates caspase 1, which in turn cleaves
pro-interleukin-1 b (IL-1b) and pro-IL-18 into their bioactive
forms (Martinon et al., 2009). The inflammasome complex is
formed upon triggering of NLR such as NLRP3 and NLRC4.
This can occur through recognition of microbial ligands such
as flagellin or through indirect mechanisms such as host lyso-
somal damage resulting from the phagocytosis of crystalline
particles (e.g., alum and uric acid). Necrotic cells release ATP
and uric acid, which activate the NLRP3 inflammasome, thereby
linking cellular damage to an inflammatory response (Hornung
et al., 2008; Iyer et al., 2009).
Mechanism of Action of Empirically Derived Adjuvants
Freund’s Adjuvant
Complete Freund’s adjuvant (CFA) is a mixture of paraffin oil and
surfactant with heat-killed Mycobacterium tuberculosis or
M. butryicum in which aqueous antigen solutions are emulsified.
Although CFA is unacceptable for human use, studies on the
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for vaccine design. Immunization with protein antigens in CFA
results in strong Th1 and Th17 cell responses that are dependent
on the mycobacterial component and require host MyD88
signaling (Shenderov et al., 2010; Su et al., 2005). Although
mycobacteria contain potent TLR2, 4, and 9 ligands, signaling
through IL-1R rather than TLR largely explains the requirement
for MyD88 in the enhancement of T cell responses. As might
be predicted, the inflammasome is also necessary for process-
ing of the IL-1 that triggers this IL-1R-mediated pathway
(Shenderov et al., 2010). In contrast, the effects of CFA on the
humoral response are inflammasome independent and the
requirement for MyD88- or TRIF-dependent signaling pathways
varies in different experimental models (Eisenbarth et al., 2008;
Gavin et al., 2006). At present, the non-TLR PRR and ligands
involved in the induction of pro-IL-1b and the inflammasome
activity required for its processing are not clearly defined.
One mycobacterial component with potent adjuvant activity is
trehalose dimycolate (cord factor) recognized by Mincle, a CLR
that signals through the Syk kinase-CARD9 pathway (Ishikawa
et al., 2009; Schoenen et al., 2010). A synthetic ligand for Mincle
formulated in liposomes (CAF01) shows promise as an adjuvant
for tuberculosis vaccines (Gram et al., 2009). Mycobacterial
peptidoglycan components previously shown to stimulate
NOD receptors are also important candidates (Fritz et al.,
2007). In addition, IL-12 p40 induction is also required for the
Th1 cell polarizing effects of CFA, and this activity probably
depends on a series of redundant signals delivered by TLR,
NLR, and CLR.
Though the mycobacterial component of CFA plays a major
role in the stimulation of cell-mediated immunity, emulsification
of antigens in paraffin oil or surfactant alone (i.e., incomplete
Freund’s adjuvant; Montanide) can sustantially boost antibody
responses. The mechanism of action of oil emulsion adjuvants
is poorly understood, although one study suggested a partial
requirement for NOD2 (Moreira et al., 2008). Nevertheless,
because these emulsions are likely to cause cellular damage
upon injection, it is tempting to speculate that endogenous
signals released during necrotic cell death may also contribute
to their adjuvant activity.
Aluminum Salts
The clinically approved alum adjuvants consist of precipitates of
aluminum phosphate and aluminum hydroxide to which antigens
are adsorbed. Although traditionally thought to function primarily
by forming a long-lasting depot for antigen and by promoting
their uptake by antigen-presenting cells (APCs), it is now clear
that innate immune stimulation plays a primary role in the
adjuvant activity of alum (Lambrecht et al., 2009; Marrack
et al., 2009). Alum is used primarily to enhance antibody produc-
tion and does not utilize TLR for its function in vivo (Gavin et al.,
2006). In humans, responses to proteins with alum tend to be
a mix of Th2 and Th1 cells (Didierlaurent et al., 2009); however,
in mice alum induces a profoundly polarized Th2 cell response,
with Th2 cell-dependent antibody isotypes, to nearly all protein
antigens. Studies in vitro employing macrophages and DCs
have demonstrated that, after lipopolysaccharide (LPS) priming,
alum can activate the NLRP3 inflammasome to produce mature
IL-1b (Li et al., 2007). This process appears to involve phagocy-
tosis of alum crystals and lysosomal release of cathepsin B intothe cytoplasm, where the enzyme localizes at the site of cas-
pase-1-associated inflammasome activity (Hornung et al.,
2008). Although the data supporting NLRP3 inflammasome
triggering by alum in vitro are compelling, there is considerable
controversy surrounding the role of this pathway in the adjuvant
activity of alum in vivo (Lambrecht et al., 2009; Marrack et al.,
2009). These conflicting findings may relate to the different
alum-antigen formulations and/or immunization protocols used
by the different laboratories involved. Whether the inflamma-
some-caspase-1-dependent processing of IL-1 and IL-18 plays
a role in the strong Th2 cell polarization triggered by alum inmice
is also not clear. Stimulation of the Th2 cell-promoting cytokines
IL-4, IL-6, and IL-25 from innate cells by alumhas been proposed
as an alternative explanation for the strong Th2 cell polarization
observed in mice (Lambrecht et al., 2009; Marrack et al., 2009;
Serre et al., 2008).
In addition to inflammasome activation by alum itself, the adju-
vant can also trigger necrotic cell death and the release of the
endogenous danger signal uric acid. Indeed, injection of uricase
has been shown to block the immunopotentiating effect of alum
administered by the intraperitoneal route (Kool et al., 2008;
Lambrecht et al., 2009). The current controversies concerning
the mechanism of action of alum adjuvants underscore the
need to determine which subset of the innate responses
provoked by an adjuvant are specifically required for enhanced
antibody or T cell responses.
Oil-in-Water Emulsions: MF59 and AS03
MF59 (Novartis) and AS03 (GlaxoSmithKline) are both oil-in-
water emulsions based on squalene, an oil that is more readily
metabolized than the paraffin oil used in Freund’s adjuvants.
MF59 is licensed in most of Europe for use with seasonal flu
vaccines in the elderly, and both are used in approved pandemic
flu vaccines. As a result, there are considerable human data
comparing flu vaccination with these adjuvants to the same
vaccine without adjuvant or with alum (Mbow et al., 2010). These
emulsions stimulate stronger antibody responses, permit fewer
doses and antigen dose sparing, and generate marked memory
responses, with a mixed Th1-Th2 cell phenotype (Ott et al.,
1995). MF59 induces substantial local stimulation, recruitment
of DCs, granulocytes, and differentiation of monocytes into
DCs (Seubert et al., 2008), as well as increased uptake of antigen
by DCs (Dupuis et al., 1998). Intramuscular injection of MF59
leads to a pattern of induced genes that is both larger and
distinct from that induced by either alum or a TLR9 agonist
(Mosca et al., 2008).
Saponin-Based Adjuvants, ISCOMs
Immunostimulatory complexes (ISCOMs) are cagelike nanopar-
ticles composed of saponins purified from the bark of a South
American tree, Quillaja saponaria, formulated with cholesterol,
phospholipid, and antigen. Vaccine antigens need not be incor-
porated into the particles, and most current applications use
a mixture of soluble antigens and the antigen-free particle,
such as ISCOMATRIX. ISCOMs do not act through any identified
PRR; however, they enhance antigen uptake and prolong reten-
tion by DCs in draining lymph nodes, induce activation of DCs,
and lead to strong antibody and T cell responses (Maraskovsky
et al., 2009). Although ISCOMs are potent enhancers of Th cells,
they do not impose a bias to either a Th1 or Th2 cell response.
Unlike most other adjuvants, ISCOMs enable substantial MHCImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 495
Immunity
Reviewclass I presentation and induce both CD8+ and CD4+ T cell
responses to a variety of soluble protein antigens in man (Davis
et al., 2004) and experimental animals. ISCOMs appear to desta-
bilize the endosomal membrane, allowing greater cytoplasmic
access for codelivered antigens compared to other forms of
antigen delivery (Schnurr et al., 2009). A heterogenous fraction
of saponins, Quil A, is widely used for veterinary vaccines, and
a highly purified species, QS-21, is currently being tested in
human studies with several vaccine candidates.
Adjuvants Targeting Pattern Recognition Receptors
In contrast to the complex and still incompletely understood
adjuvants described above, an increasing focus has been to
use natural ligands or synthetic agonists for well-defined PRRs
as adjuvants, either alone or with various formulations. A number
of these are now in clinical or late preclinical stages of develop-
ment for multiple applications and have been the subject of
research to clarify the basis of their adjuvant activity.
TLR3 and RLR Ligands
The discovery that double-stranded viral RNA (dsRNA) is
a potent activator of innate immunity was a seminal finding for
understanding host immunity against viral infection (Alexopoulou
et al., 2001). Synthetic analogs of dsRNA (i.e., Poly IC) have been
used as adjuvants (Longhi et al., 2009; Stahl-Hennig et al., 2009;
Trumpfheller et al., 2008) and can act through two distinct types
of PRRs. Viral or synthetic dsRNA activates TLR3 in endosomes
(Alexopoulou et al., 2001) or through cytosolic ribonucleic acid
(RNA) helicases (RLR), such as retinoic acid-inducible gene-1
(RIG-I) and melanoma differentiation associated gene 5 (MDA5)
(Kato et al., 2006). TLR3mediates its effects through the adaptor
TRIF (Alexopoulou et al., 2001), whereas RLR signal through the
adaptor IFN-B promoter stimulatory-1 (Kato et al., 2006).
TLR3 activation in DCs induces IL-12 and type I IFN and
improves MHC class II expression and cross-presentation
(Davey et al., 2010; Jongbloed et al., 2010; Kadowaki et al.,
2001; Lore et al., 2003; Poulin et al., 2010; Schulz et al., 2005;
Wang et al., 2010). Stimulation ofMDA-5,most notably fromnon-
hematopoietic cells (Longhi et al., 2009; Wang et al., 2010),
strongly enhances production of type I IFNs. Type I IFNs play
a critical role in enhancing T and B cell immunity with dsRNA
through a variety of mechanisms that include activation of DCs,
NK cells, and direct effects on T cells (Blanco et al., 2001; Le
Bon et al., 2006; Longhi et al., 2009). Several synthetic analogs
of dsRNA (Poly IC, Poly ICLC, and Poly IC12U) have been used
as adjuvantswith soluble proteins, DC targeting constructs, or in-
activated viral vaccines (Gowen et al., 2007; Stahl-Hennig et al.,
2009; Trumpfheller et al., 2008). Poly IC activates both TLR3
andMDA, whereas Poly IU signals through TLR3 only. Activation
of both TLR3 and MDA5 optimizes the magnitude and durability
of Th1 cell immunity andCD8+ T cell immunity compared to either
pathway alone. This highlights a central feature of the potency of
Poly IC by inducing TLR3 activation of DCs directly and type I
IFNs through MDA-5 (Longhi et al., 2009).
The formulation of Poly IC has a critical influence on its
potency. Thus, long dsRNA is required to activate MDA-5
(Kato et al., 2008). Furthermore, complexing Poly IC with
poly-L-lysine and carboxymethylcellose (poly ICLC) prolongs
the adjuvant effect in vivo (Levy et al., 1975; Stahl-Hennig
et al., 2009). Collectively, an optimally formulated Poly IC is an496 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.effective adjuvant for inducing broad-based adaptive immunity
through both TLR and RLR signaling pathways.
TLR4 Ligands
Bacterial lipopolysaccharides have long been recognized as
potent adjuvants, but their pyrogenic activity has precluded
use as an adjuvant in man. Pioneering work from Ribi (Qureshi
et al., 1982) led to the development of less toxic preparations
of LPS, and ultimately to the substantially detoxified derivative
monophosphoryl lipid A (MPL). MPL, principally formulated
with antigens and alum, is now a component of licensed
vaccines for HBV and papilloma and has proven to be both
safe and effective (Casella and Mitchell, 2008). Both LPS and
MPL are recognized specifically by TLR4, but MPL leads to
signaling only through the TRIF adaptor, whereas LPS leads to
TLR4 activation through both the TRIF and MyD88 pathways
(Mata-Haro et al., 2007), the latter pathway resulting in high
levels of many inflammatory cytokines, prominently TNF-a.
MPL formulated on alum (AS04) stimulates a polarized Th1 cell
response in contrast to the mixed Th1-Th2 cell response of
alum alone (Casella and Mitchell, 2008; Didierlaurent et al.,
2009). Much of the adjuvant activity of this mixture can be
attributed to the MPL component, although alum helps prolong
stimulation by MPL (Didierlaurent et al., 2009).
TLR5 Ligands
Bacterial flagellin has long been known to be a potent T cell-inde-
pendent antigen, but the finding that flagellin from many species
was a ligand for TLR5 suggested its potential as an adjuvant.
Although flagellin itself can be an adjuvant when mixed with
antigens, current application is primarily by generation of fusion
proteins of recombinant vaccine antigens and flagellin (Huleatt
et al., 2007). Unlike many other TLR agonists, flagellin tends to
produce mixed Th1 and Th2 cell responses rather than strongly
polarized Th1 cell patterns (Huleatt et al., 2007). Antibody
production to fusion proteins requires TLR5 expression
(McDonald et al., 2007), but optimum adjuvant effect in mice
requires expression of the TLR signaling adaptor MyD88 in
both hematopoietic and nonhematopoeitic (radioresistant) cell
types (Sanders et al., 2008). Bacterial flagellins can also signal
through inflammasomes that contain Nlrc4 (also known as
IPAF) (Miao and Warren, 2010), although it is not known whether
this pathway contributes to the adjuvant activity of flagellin.
TLR7 and TLR8 Ligands
Guanosine- and uridine-rich ssRNA were first identified as
natural agonists for TLR7 and 8 (Diebold et al., 2004; Heil
et al., 2004; Lund et al., 2004). Because ssRNA is rapidly
degraded by extracellular RNases, using it as an adjuvant
without substantial modification or formulation is unpromising.
However, a number of small synthetic compounds originally
developed as type I IFN inducers, including imidazoquinolines
(Imiquimod, TLR7 and Resiquimod, TLR7-TLR8) and guanosine
and adenosine analogs, have been shown to activate TLR7,
TLR8, or both (Gorden et al., 2005; Heil et al., 2003; Hemmi
et al., 2002). TLR7 and TLR8 are expressed in endosomes, but
not on the cell surface, and both mediate their effects through
MyD88-dependent signaling (Hemmi et al., 2002).
Important differences exist between mice and humans with
regard to tissue expression and function of TLR7 and TLR8. In
both species, TLR7 is expressed in B cells, neutrophils, and plas-
macytoid DCs (pDCs); however, in mice TLR7 is expressed by
Immunity
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Medzhitov, 2004). TLR8, in contrast, is expressed by monocyte
lineage cells and myeloid DCs in man, whereas it may not be
a functional receptor in mice (Jurk et al., 2002). Activation of
TLR7 and TLR8 in human pDCs and mDCs, respectively,
increases the expression of costimulatory molecules and
production of type I IFN and IL-12 (Jarrossay et al., 2001;
Kadowaki et al., 2001; Lore et al., 2003). A bispecific TLR7-
TLR8 agonist may bemore effective than amonospecific agonist
by activatingmultiple DC subsets andB cells to induce cytokines
optimal for Th1 cell immunity, cross-presentation, and antibody
production. Small TLR7 or 8 agonists are not very effective as
adjuvants when simply mixed with antigens, but can be substan-
tially improved by formulation with or conjugation to the antigen
(Wille-Reece et al., 2005, 2006; Wu et al., 2007).
TLR9—CpG-ODN and Formulated DNA
TLR9 is the only endosomal PRR specific for DNA and mediates
a potent innate response to bacterial and viral DNA (Blasius and
Beutler, 2010). Sequence motifs containing the CpG dinucleo-
tide are preferentially recognized; however, specific base
sequences only partly account for TLR9 binding. The sugar-
phosphate backbone is also integral to recognition by TLR9
(Haas et al., 2008). Synthetic 18–25 base oligodeoxynucleotides
(ODN) with optimized CpGmotifs (CpG-ODN) have been studied
extensively as adjuvants, either soluble or formulated in
nanoparticles (Marshall et al., 2004) or virus-like particles
(Jennings and Bachmann, 2009). CpG-ODN enhance antibody
responses and strongly polarize Th cell responses to Th1 and
away from Th2 cell responses (Kobayashi et al., 1999; Tighe
et al., 2000). TLR9 has a relatively restricted cellular distribution,
especially in man, with the two major APC types being B cells
and pDCs (Campbell et al., 2009). Studies with a DC-specific
deletion of TLR signaling in mice indicate that DC recognition
is much more important for the antibody-enhancing activity of
CpG-ODN than B cell expression (Hou et al., 2008). However,
in primates, myeloid DCs, thought to be the principal antigen-
presenting DCs, are TLR9 negative, suggesting either that
activated PDC are sufficient for the adjuvant effect of CpG-ODN
or that myeloid DCs become activated in the lymph node by indi-
rect means (Teleshova et al., 2006).
What Have We Learned from Studies of Vaccines
and Adjuvants?
Codelivery of Antigens and PRR Ligands Enhances
Effectiveness
The immune system is optimized to generate adaptive
responses to microbial antigens delivered to APCs in intimate
association with PRR ligands, as would be the case for viral
and microbial infections and live attenuated vaccines. For
subunit vaccine candidates, codelivery has been accomplished
by covalent coupling of TLR7-TLR8 (Wille-Reece et al., 2005;Wu
et al., 2007) and TLR9 (Tighe et al., 2000) to purified proteins or
by constructing recombinant fusion proteins consisting of
antigen and the TLR5 ligand flagellin (Huleatt et al., 2007).
In these examples, the potency of the linked vaccine is 10–100
times that of a comparable mix of separate components. In the
case of CpG-ODN conjugates, coupling of an ODN enhances
antigen uptake and cross-presentation in DCs, although the
enhanced uptake is not TLR9 dependent (Heit et al., 2003). Co-delivery of antigens and PRR ligands can also be accomplished
by association—covalent or noncovalent—of both within a larger
particulate structure. Examples include virus-like particles
(Jennings and Bachmann, 2009) and synthetic nano- and micro-
particles (O’Hagan and De Gregorio, 2009).
The enhanced efficiency of this codelivery may be simply
quantitative—uptake of enough linked antigen for effective
presentation will inherently provide a stimulatory amount of the
linked PRR ligand, and enhanced uptake would lead to preferen-
tial presentation of the linked antigen. However, codelivery may
also lead to preferential handling of antigens associated with
PRR ligands, by facilitating antigen presentation at the level of
individual lysosomes (Iwasaki and Medzhitov, 2010). A number
of vaccine candidates with this strategy have reached early
stage clinical studies, and this represents one of the most
promising new directions in vaccine development.
Adjuvants Can Work through Both Direct and Indirect
Actions on APCs
A critical scientific and practical aspect of rational vaccine
design is whether DCs presenting antigen need to be synchro-
nously activated for optimal antigen presentation and effective
Th1 and CD8+ T cell priming. Several key studies (Blander and
Medzhitov, 2006; Joffre et al., 2009; Sporri and Reis e Sousa,
2005) have shown that TLR activation in the same DC presenting
the antigen is critical for CD4+ T cell activation and Th1 cell differ-
entiation. Moreover, mouse (Bedoui et al., 2009; Schulz et al.,
2005) or human (Jongbloed et al., 2010; Poulin et al., 2010) DC
subsets specialized for cross-presentation show increased
CD8+ T cell immunity when Poly IC is used to activate cells
through TLR3. However, more recent evidence shows produc-
tion of type I IFNs from DCs or nonhematopoietic stromal cells
not presenting the antigen can profoundly influence Th1 (Hou
et al., 2008) and CD8+ T cell immunity (Longhi et al., 2009;
Wang et al., 2010). Induction of these type I IFNs can result
from TLR-dependent activation of pDCs or MyD88-independent
production from non-DCs (Hou et al., 2008) or through MDA-5
from nonhematopoietic stromal cells (Longhi et al., 2009;
Trumpfheller et al., 2008; Wang et al., 2010). Overall, codelivery
of antigen and adjuvant to the sameDC and a bystander produc-
tion of type I IFN may be required for optimizing T cell immunity.
Thus, Poly IC and TLR7-TLR8, which induce an optimal cytokine
milieu (IL-12 and type I IFN-a) and are able to directly activate
DC subsets specialized for CD4 activation and cross-presenta-
tion, offer great promise as adjuvants (Figure 1).
Multiple Innate Stimuli Can Be Better than One
One important lesson from studies of live attenuated vaccines is
that activation of multiple innate receptorsmay bemore effective
than activation of a single pathway (Querec et al., 2006). This
is logical, because redundant pathways of innate responsive-
ness would increase the likelihood of dealing successfully with
an infection via a limited number of PRRs. Studies in vitro with
defined combinations of TLR ligands support this idea (Trinchieri
and Sher, 2007) and suggest combinations that may be
especially useful for adjuvants. The very effective adjuvant
systems developed by GlaxoSmithKline take this approach,
combining MPL and alum (AS04) or MPL, QS-21, and either
oil-in-water emulsion (AS02) or liposomes (AS01), and many
more combinations are in late preclinical or early clinical stages
of development.Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 497
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Figure 1. PRR Ligands Shape Adaptive T Cell Immunity through Direct and Indirect Effects on Dendritic Cells
(A) Expression of PRRs in human antigen-presenting and nonhematopoietic cells. The ability of the corresponding PRR ligands to produce cytokines and induce
Th1 cell and cross-presentation from such cells is depicted below. MPL-based adjuvants (ASO1, ASO2, ASO4) activate monocyte and myeloid DCs, whereas
TLR7 (Imiquimod) and TLR9 (CpG) ligands activate pDCs. Such adjuvants induce Th1 cell and low-level CD8+ T cell responses. In humans, it is not clear whether
these cells contribute to cross-priming in vivo.
(B) The influence of direct innate activation and antigen presentation, bystander innate immunity on antigen presentation, or both together are shown. The relative
potency of Th1 cell and CD8+ T cell immunity from these respective pathways are derived from in vivomouse studies. Optimal Th1 cell and CD8+ T cell immunity is
elicited by direct activation of antigen-presenting cells and bystander production of type I IFN. This can be achieved by using Poly IC and TLR7-TLR8 ligands as
adjuvants, with the source of type I IFN derived from nonhematopoetic and pDCs, respectively.
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to Develop the Most Appropriate Response
Rational vaccine design is guided by understanding the
immune correlates of protection and then selecting vaccines
or adjuvants to elicit such responses. In Table 1, the type of
adaptive immune responses induced in mice and/or humans
with various adjuvants and formulations are shown. The clear-
est example in man of how alterations in vaccine formulation
improve immunogenicity and protection is the RTS,S vaccine.498 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.RTS,S is a complex formulation comprised of a circumsporo-
zoite protein and hepatitis B surface antigen fusion protein.
Initial studies showed that RTS,S administered with alum
elicited circumsporozoite-specific antibody, but did not confer
protection (Stoute et al., 1997). However, when RTS,S is mixed
with the TLR4 ligand, MPL, QS-21, and oil-in-water (AS02A) or
liposome (AS01B) formulation, there is increased antibody
production and induction of Th1 cell immunity with 30%–
50% protection (Kester et al., 2009). Moreover, both Th1 cell
Immunity
Reviewand humoral immunity are increased with AS01B compared to
AS02A.
Animal Models and In Vitro Systems Have Important
Limitations
The most widely used tools for both preclinical evaluation and
mechanistic studies of adjuvants are activation of antigen-
presenting cells in vitro and immunity in experimental rodent
models. As noted in previous sections, there can be substantial
discordance in the responses of rodents and humans to complex
adjuvants or defined PRR ligands. Differences in the cellular
expression patterns of PRR can often account for this, as
illustrated by the functional consequences of distinct rodent
and human patterns of TLR9 expression (Campbell et al.,
2009). Many studies defining receptors and pathways of
adjuvant activity employ genetically modified mice; however,
the experimental conditions used often do not reflect the prac-
tice of human vaccination. In particular, many such mouse
studies use intraperitoneal or intravenous injection rather than
the subcutaneous or intramuscular routes used in clinical
application. Different routes can lead to differential antigen
presentation by specific DC subsets.
For example, dermal DCs and Langerhans cells play distinc-
tive roles in adaptive immunity (Klechevsky et al., 2008). In addi-
tion, antigen doses used in mice are frequently higher that would
be used for a typical recombinant vaccine in humans, and
variables such timing and experimental readout can differ
between mouse and human studies. The contribution of these
variables to the interpretation of mechanistic experiments in
mice has not been carefully examined. However, the choice of
the experimental antigen itself can clearly affect the outcome
of such studies. The dependence of several adjuvants on
MyD88- and TRIF-linked signaling pathways can be quite
different between studies with haptenated versus those with
unmodified protein antigens (Palm and Medzhitov, 2009).
Ovalbumin, an antigen widely used in mouse studies, tends to
be cross-presented more readily than most other proteins.
Hence the impressive cross-priming of CD8+ T cells with oval-
bumin may not necessarily represent results obtainable with
more typical vaccine antigens.
Similarly, studies with blood cells in vitro have substantial limi-
tations in evaluating adjuvants. Cell cultures are not useful for
studying formulations that rely on inflammatory cytokine
responses from noncirculating tissue cells. Adjuvants that act
in part by altering the anatomical distribution of antigen or its
persistence at the injection site may likewise not be easily
studied in cell cultures.
An important consideration in selecting adjuvants for clinical
use is to establish a model that will be predictive for responses
in humans. Although humanized mice can be used to assess
the effectiveness of adjuvants on innate immunity, such mice
may be limited at present to assess adaptive responses over
a prolonged period of time. A second tool is to develop mice
that have similar cell-specific expression of innate signaling
pathways as humans. The remaining alternative is to use non-
human primates (NHP). Because NHP are more similar to
humans than are mice with regard to DC subsets and PRR
expression, they may offer a useful alternative for evaluating
both potency and mechanism of novel adjuvants. The ability to
do more invasive sampling and to evaluate adjuvants that havenot yet met the regulatory requirements for testing in humans
makes mechanistic studies in non-human primates an excellent
bridge between rodents and humans. The major issue for using
NHP is the availability of animals and the high cost of maintaining
them, which often limits the size of animal groups.
Innate Immunity and Adjuvant Safety
The adoption of new adjuvants into licensed vaccines has been
slowed by a variety of hypothetical safety concerns, especially
the possibility of an increased risk of autoimmune disease. These
concerns are based in part on two sets of observations. Infec-
tions can trigger or exacerbate some autoimmune diseases,
and this can often be tied to elements of the innate response.
For example, type 1 IFNs are important in the pathogenesis of
lupus, and disease flares are often triggered by viral infections
(Zandman-Goddard and Shoenfeld, 2005). Second, PRR ligands
are capable of breaking tolerance in animal models, for example,
by overcoming inhibition by regulatory T cells (Pasare and
Medzhitov, 2003). Repeated injection with IFN-inducing PRR
ligands can also enhance the growth and pathogenicity of
M. tuberculosis in mouse models (Antonelli et al., 2010).
Consideration of several important differences between live
infections and adjuvanted subunit vaccines can put these
theoretical concerns in perspective. Innate immune stimulation
with nonliving vaccines is short-lived and focused on a local
injection site and its draining lymphatic. Second, adjuvants are
engineered to enhance the response to immunogenic non-self
antigens and few, if any, provide all of the activities needed to
render a self-antigen sufficiently immunogenic to trigger autoim-
munity, even if autoreactive T cells are present. Perhaps the
most compelling argument is the fact that many of the most
widely used and safest vaccines—the live, attenuated viral and
bacterial vaccines—rely on activation through multiple PRR,
yet have not been linked to an increased risk of any autoimmune
disease. Similarly, the large human safety databases obtained
with vaccines using either MF59 (Pellegrini et al., 2009) or
AS04 (Verstraeten et al., 2008), both approved for human use
in multiple countries, as well as more limited experience with
several advanced experimental vaccines, have failed to support
an increase in autoimmune or infectious diseases with these
newer adjuvants.
Conclusion
Adjuvants have long been of great interest to vaccine de-
velopers but considered a necessary, if uninteresting, conve-
nience to basic immunologists. Advances of the past decade in
understanding innate immunity have brought a wider interest in
understanding how existing adjuvants work and how they might
be improved. All adjuvants appear to stimulate components of
the innate immune system, but the diversity of mechanisms
used by even a short list of well-studied adjuvants is impressive.
Adjuvants currently used in humans enhance humoral immunity,
but many new adjuvants in clinical or preclinical development are
focused on enhancing specific types of T cell responses and
generating the multifaceted immune responses that may be
needed for challenging diseases such as malaria and HIV-AIDS.
Althoughwell-defined ligands for PRR have attractedmost of the
attention, it is clear that strategies for formulation and delivery of
subunit vaccines can profoundly influence T cell immunity, mostImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 499
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Reviewnotably by facilitating cross-presention of antigen by DCs. Along
the path of development of new vaccines and adjuvants lies an
unparalleled opportunity to study the immune responses of large
populations of basically healthy humans. No other form of
defined ‘‘experimental’’ challenge can be as easily and ethically
given to humans, and mechanistic studies incorporated as part
of the clinical development of new adjuvants can teach us a great
deal about the human immune system.ACKNOWLEDGMENTS
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